Hemophilia A and Hemophilia B

[1]  D. Perry,et al.  AAV5–Factor VIII Gene Transfer in Severe Hemophilia A , 2017, The New England journal of medicine.

[2]  Kim Yong Jae,et al.  Molecular Design and Characterization of a Novel, Vwf Independent Coagulation Factor VIII (LAFATE) , 2017 .

[3]  J. Rasko,et al.  Hemophilia B Gene Therapy with a High‐Specific‐Activity Factor IX Variant , 2017, The New England journal of medicine.

[4]  Zaina T. Al-Salama,et al.  Lonoctocog Alfa: A Review in Haemophilia A , 2017, Drugs.

[5]  P. Jiang,et al.  Noninvasive detection of F8 int22h-related inversions and sequence variants in maternal plasma of hemophilia carriers. , 2017, Blood.

[6]  J. Oldenburg,et al.  Emicizumab Prophylaxis in Hemophilia A with Inhibitors , 2017, The New England journal of medicine.

[7]  A. Akinc,et al.  Targeting of Antithrombin in Hemophilia A or B with RNAi Therapy , 2017, The New England journal of medicine.

[8]  J. Astermark,et al.  Discrepancies between the one‐stage clotting assay and the chromogenic assay in haemophilia B , 2017, Haemophilia : the official journal of the World Federation of Hemophilia.

[9]  V. Blanchette,et al.  A systematic review of ultrasound imaging as a tool for evaluating haemophilic arthropathy in children and adults , 2017, Haemophilia : the official journal of the World Federation of Hemophilia.

[10]  A. Nienhuis,et al.  Gene Therapy for Hemophilia. , 2017, Molecular therapy : the journal of the American Society of Gene Therapy.

[11]  D. Perry,et al.  Treatment of bleeding episodes with recombinant factor VIII Fc fusion protein in A‐LONG study subjects with severe haemophilia A , 2017, Haemophilia : the official journal of the World Federation of Hemophilia.

[12]  S. Kitchen,et al.  Factor Activity Assays for Monitoring Extended Half-Life FVIII and Factor IX Replacement Therapies , 2017, Seminars in Thrombosis and Hemostasis.

[13]  O. Stasyshyn,et al.  Extended half‐life pegylated, full‐length recombinant factor VIII for prophylaxis in children with severe haemophilia A , 2017, Haemophilia : the official journal of the World Federation of Hemophilia.

[14]  I. Pabinger,et al.  Safety and efficacy of BAY 94‐9027, a prolonged‐half‐life factor VIII , 2017, Journal of thrombosis and haemostasis : JTH.

[15]  P. Sax,et al.  Ledipasvir–sofosbuvir and sofosbuvir plus ribavirin in patients with chronic hepatitis C and bleeding disorders , 2017, Haemophilia : the official journal of the World Federation of Hemophilia.

[16]  R. Ljung,et al.  Primary prophylaxis in haemophilia care: Guideline update 2016. , 2017, Blood cells, molecules & diseases.

[17]  K. Fischer,et al.  Recombinant factor IX Fc fusion protein in children with haemophilia B (Kids B-LONG): results from a multicentre, non-randomised phase 3 study. , 2017, The Lancet. Haematology.

[18]  J. Oldenburg,et al.  Long-term safety and efficacy of extended-interval prophylaxis with recombinant factor IX Fc fusion protein (rFIXFc) in subjects with haemophilia B. , 2016, Thrombosis and haemostasis.

[19]  J. Hernández-Rivas,et al.  Application of a molecular diagnostic algorithm for haemophilia A and B using next-generation sequencing of entire F8, F9 and VWF genes , 2016, Thrombosis and Haemostasis.

[20]  F. Peyvandi,et al.  Advances in the treatment of bleeding disorders , 2016, Journal of thrombosis and haemostasis : JTH.

[21]  A. Iorio,et al.  The use of pharmacokinetics in dose individualization of factor VIII in the treatment of hemophilia A , 2016, Expert opinion on drug metabolism & toxicology.

[22]  E. Santagostino,et al.  Nonacog beta pegol in previously treated children with hemophilia B: results from an international open‐label phase 3 trial , 2016, Journal of thrombosis and haemostasis : JTH.

[23]  M. Schemper,et al.  FVIII-binding IgG modulates FVIII half-life in patients with severe and moderate hemophilia A without inhibitors. , 2016, Blood.

[24]  V. Ramanan,et al.  A Randomized Trial of Factor VIII and Neutralizing Antibodies in Hemophilia A. , 2016, The New England journal of medicine.

[25]  T. Humphries,et al.  Inhibitors in haemophilia A: a perspective on clotting factor products as a potential contributing factor , 2016, Haemophilia : the official journal of the World Federation of Hemophilia.

[26]  J. Peterson,et al.  Targeting TFPI for hemophilia treatment. , 2016, Thrombosis research.

[27]  F. Horling,et al.  Porcine recombinant factor VIII (Obizur; OBI‐1; BAX801): product characteristics and preclinical profile , 2016, Haemophilia : the official journal of the World Federation of Hemophilia.

[28]  K. Lyseng-Williamson.  Coagulation Factor IX (Recombinant), Albumin Fusion Protein (Albutrepenonacog Alfa; Idelvion®): A Review of Its Use in Haemophilia B , 2016, Drugs.

[29]  B. Konkle,et al.  Aging among persons with hemophilia: contemporary concerns. , 2016, Seminars in hematology.

[30]  A. Srivastava.  Inflammation is key to hemophilic arthropathy. , 2015, Blood.

[31]  L. Spate,et al.  Engineering protein processing of the mammary gland to produce abundant hemophilia B therapy in milk , 2015, Scientific Reports.

[32]  A. S. Eraghi,et al.  The long-term effects of radioactive phosphorous synoviorthesis on hemophilic arthropathy. , 2015, Blood cells, molecules & diseases.

[33]  S. Milstein,et al.  An RNAi therapeutic targeting antithrombin to rebalance the coagulation system and promote hemostasis in hemophilia , 2015, Nature Medicine.

[34]  J. Oldenburg,et al.  Affinity of FVIII-specific antibodies reveals major differences between neutralizing and nonneutralizing antibodies in humans. , 2015, Blood.

[35]  J. Oldenburg,et al.  Recombinant long-acting glycoPEGylated factor IX in hemophilia B: a multinational randomized phase 3 trial. , 2014, Blood.

[36]  Cassandra Willyard.  Thrombosis: Balancing act , 2014, Nature.

[37]  E. Santagostino,et al.  Inhibitors – genetic and environmental factors , 2014, Haemophilia : the official journal of the World Federation of Hemophilia.

[38]  J. Dumont,et al.  Phase 3 study of recombinant factor IX Fc fusion protein in hemophilia B. , 2013, The New England journal of medicine.

[39]  R. Schaub,et al.  Aptamer BAX 499 mediates inhibition of tissue factor pathway inhibitor via interaction with multiple domains of the protein , 2013, Journal of thrombosis and haemostasis : JTH.

[40]  J. Oldenburg,et al.  Intensity of factor VIII treatment and inhibitor development in children with severe hemophilia A: the RODIN study. , 2013, Blood.

[41]  E. Rodríguez‐Merchán.  Local fibrin glue and chitosan-based dressings in haemophilia surgery , 2012, Blood coagulation & fibrinolysis : an international journal in haemostasis and thrombosis.

[42]  N. Okada,et al.  Liver transplantation for a pediatric patient with hemophilia B , 2012, Pediatric Transplantation.

[43]  P. Kouides,et al.  How we manage prostate biopsy and prostate cancer therapy in men with haemophilia , 2012, Haemophilia : the official journal of the World Federation of Hemophilia.

[44]  J. Dumont,et al.  Safety and prolonged activity of recombinant factor VIII Fc fusion protein in hemophilia A patients. , 2012, Blood.

[45]  L. Valentino,et al.  A randomized comparison of two prophylaxis regimens and a paired comparison of on-demand and prophylaxis treatments in hemophilia A management , 2012, Journal of thrombosis and haemostasis : JTH.

[46]  C. Hay,et al.  The principal results of the International Immune Tolerance Study: a randomized dose comparison. , 2012, Blood.

[47]  A. Neff,et al.  Survey of current prophylaxis practices and bleeding characteristics of children with severe haemophilia A in US haemophilia treatment centres , 2012, Haemophilia : the official journal of the World Federation of Hemophilia.

[48]  R. Kruse-Jarres.  Current controversies in the formation and treatment of alloantibodies to factor VIII in congenital hemophilia A. , 2011, Hematology. American Society of Hematology. Education Program.

[49]  M. Callaghan,et al.  What is the evidence for the use of immunomodulatory agents to eradicate inhibitory antibodies in patients with severe hemophilia a who have previously failed to respond to immune tolerance induction? , 2011, Hematology. American Society of Hematology. Education Program.

[50]  P. Cortesi,et al.  Anti-inhibitor coagulant complex prophylaxis in hemophilia with inhibitors. , 2011, The New England journal of medicine.

[51]  P. Giangrande,et al.  Enhanced pharmacokinetic properties of a glycoPEGylated recombinant factor IX: a first human dose trial in patients with hemophilia B. , 2011, Blood.

[52]  K. High,et al.  Gene therapy for haemophilia: a long and winding road , 2011, Journal of thrombosis and haemostasis : JTH.

[53]  Hojun Li,et al.  In vivo genome editing restores hemostasis in a mouse model of hemophilia , 2011, Nature.

[54]  J. Oldenburg,et al.  Association between phenotype and genotype in carriers of haemophilia A , 2011, Haemophilia : the official journal of the World Federation of Hemophilia.

[55]  J. Astermark,et al.  Physical activity and joint function in adults with severe haemophilia on long-term prophylaxis , 2011, Blood coagulation & fibrinolysis : an international journal in haemostasis and thrombosis.

[56]  J. Li,et al.  Impact of HIV on liver fibrosis in men with hepatitis C infection and haemophilia , 2011, Haemophilia : the official journal of the World Federation of Hemophilia.

[57]  J. Ironside.  Variant Creutzfeldt–Jakob disease , 2010, Haemophilia : the official journal of the World Federation of Hemophilia.

[58]  P. Kouides,et al.  How do we treat: upper gastrointestinal bleeding in adults with haemophilia , 2010, Haemophilia : the official journal of the World Federation of Hemophilia.

[59]  P. Kouides,et al.  How we treat: patients with haemophilia undergoing screening colonoscopy , 2010, Haemophilia : the official journal of the World Federation of Hemophilia.

[60]  Carolyn J Foley,et al.  Coronary atherosclerosis and cardiovascular mortality in hemophilia , 2010, Journal of thrombosis and haemostasis : JTH.

[61]  P. Mannucci,et al.  How I treat age-related morbidities in elderly persons with hemophilia. , 2009, Blood.

[62]  R. Fimmers,et al.  Impact of polymorphisms of the major histocompatibility complex class II, interleukin‐10, tumor necrosis factor‐α and cytotoxic T‐lymphocyte antigen‐4 genes on inhibitor development in severe hemophilia A , 2009, Journal of thrombosis and haemostasis : JTH.

[63]  E. Rogaev,et al.  Genotype Analysis Identifies the Cause of the “Royal Disease” , 2009, Science.

[64]  C. Kessler,et al.  Emerging clinical concerns in the ageing haemophilia patient , 2009, Haemophilia : the official journal of the World Federation of Hemophilia.

[65]  M. Manco‐Johnson,et al.  Athletic Participation in Severe Hemophilia: Bleeding and Joint Outcomes in Children on Prophylaxis , 2009, Pediatrics.

[66]  T. Orfeo,et al.  Empirical and theoretical phenotypic discrimination , 2009, Journal of thrombosis and haemostasis : JTH.

[67]  G. Roosendaal,et al.  Treatment of ischaemic heart disease in haemophilia patients: an institutional guideline , 2009, Haemophilia : the official journal of the World Federation of Hemophilia.

[68]  L. Almasy,et al.  Inhibitors of factor VIII in black patients with hemophilia. , 2009, The New England journal of medicine.

[69]  A. Girolami,et al.  Hemospermia in Patients with Congenital Coagulation Disorders: A Study of Three Cases , 2009, Acta Haematologica.

[70]  M. Verhaar,et al.  Cardiovascular disease in patients with hemophilia , 2009, Journal of thrombosis and haemostasis : JTH.

[71]  K. Åkesson,et al.  Long‐term prophylaxis in severe haemophilia seems to preserve bone mineral density , 2009, Haemophilia : the official journal of the World Federation of Hemophilia.

[72]  G. Young,et al.  Single 270 μg kg−1‐dose rFVIIa vs. standard 90 μg kg−1‐dose rFVIIa and APCC for home treatment of joint bleeds in haemophilia patients with inhibitors: a randomized comparison , 2008, Haemophilia : the official journal of the World Federation of Hemophilia.

[73]  M. Bullinger,et al.  The economics of haemophilia prophylaxis: governmental and insurer perspectives. PROCEEDINGS OF THE SECOND INTERNATIONAL PROPHYLAXIS STUDY GROUP (IPSG) SYMPOSIUM , 2007, Haemophilia : the official journal of the World Federation of Hemophilia.

[74]  B. Konkle,et al.  Randomized, prospective clinical trial of recombinant factor VIIa for secondary prophylaxis in hemophilia patients with inhibitors , 2007, Journal of thrombosis and haemostasis : JTH.

[75]  Alan R. Cohen,et al.  Prophylaxis versus episodic treatment to prevent joint disease in boys with severe hemophilia. , 2007, The New England journal of medicine.

[76]  S. Darby,et al.  Mortality rates, life expectancy, and causes of death in people with hemophilia A or B in the United Kingdom who were not infected with HIV. , 2007, Blood.

[77]  J. G. van der Bom,et al.  Treatment-related risk factors of inhibitor development in previously untreated patients with hemophilia A: the CANAL cohort study. , 2007, Blood.

[78]  G. Young,et al.  Individualization of bypassing agent treatment for haemophilic patients with inhibitors utilizing thromboelastography , 2006, Haemophilia : the official journal of the World Federation of Hemophilia.

[79]  F. Rosendaal,et al.  Mortality and causes of death in patients with hemophilia, 1992–2001: a prospective cohort study 1 , 2006, Journal of thrombosis and haemostasis : JTH.

[80]  Christine A. Lee,et al.  Detection of known haemophilia B mutations and carrier testing by microarray. , 2005, Thrombosis and haemostasis.

[81]  S. Pipe.  The promise and challenges of bioengineered recombinant clotting factors , 2005, Journal of thrombosis and haemostasis : JTH.

[82]  M. Manco-Johnson,et al.  Leukemia and P32 radionuclide synovectomy for hemophilic arthropathy , 2005, Journal of thrombosis and haemostasis : JTH.

[83]  P. Babyn,et al.  Reliability of progressive and additive MRI scoring systems for evaluation of haemophilic arthropathy in children: Expert MRI Working Group of the International Prophylaxis Study Group , 2005, Haemophilia : the official journal of the World Federation of Hemophilia.

[84]  G. Dolan,et al.  Mutation analysis in 51 patients with haemophilia A: report of 10 novel mutations and correlations between genotype and clinical phenotype , 2005, Haemophilia : the official journal of the World Federation of Hemophilia.

[85]  C. Kessler,et al.  B‐domain deleted recombinant factor VIII preparations are bioequivalent to a monoclonal antibody purified plasma‐derived factor VIII concentrate: a randomized, three‐way crossover study , 2005, Haemophilia : the official journal of the World Federation of Hemophilia.

[86]  S. Lethagen,et al.  Intranasal desmopressin (DDAVP) by spray in mild hemophilia A and von Willebrand's disease type I , 1990, Blut.

[87]  J. Lusher,et al.  Is the incidence and prevalence of inhibitors greater with recombinant products? No , 2004, Journal of thrombosis and haemostasis : JTH.

[88]  J. Ingerslev,et al.  Collaborative field study on the utility of a BDD factor VIII concentrate standard in the estimation of BDDr Factor VIII:C activity in hemophilic plasma using one‐stage clotting assays , 2004, Journal of thrombosis and haemostasis : JTH.

[89]  L. Valentino.  Secondary prophylaxis therapy: what are the benefits, limitations and unknowns? , 2004, Haemophilia : the official journal of the World Federation of Hemophilia.

[90]  A. Cumming.  The factor VIII gene intron 1 inversion mutation: prevalence in severe hemophilia A patients in the UK , 2004, Journal of thrombosis and haemostasis : JTH.

[91]  J. Oldenburg,et al.  Environmental and genetic factors influencing inhibitor development. , 2004, Seminars in hematology.

[92]  A. Goodeve.  The incidence of inhibitor development according to specific mutations - and treatment? , 2003, Blood coagulation & fibrinolysis : an international journal in haemostasis and thrombosis.

[93]  G. Mariani,et al.  Immune Tolerance Induction in Hemophilia A: A Review , 2003, Seminars in thrombosis and hemostasis.

[94]  M. Manco‐Johnson,et al.  32P Radiosynoviorthesis in Children With Hemophilia , 2002, Journal of pediatric hematology/oncology.

[95]  J. Katz,et al.  The North American Immune Tolerance Registry: Practices, Outcomes, Outcome Predictors , 2002, Thrombosis and Haemostasis.

[96]  G. Gilchrist,et al.  Intrauterine correction of factor VIII (FVIII) deficiency , 2001, Haemophilia : the official journal of the World Federation of Hemophilia.

[97]  J. Astermark,et al.  The Malmö International Brother Study (MIBS): further support for genetic predisposition to inhibitor development , 2001, Haemophilia : the official journal of the World Federation of Hemophilia.

[98]  J. Lusher,et al.  Perinatal management of newborns with haemophilia , 2001, British journal of haematology.

[99]  K. Mann,et al.  Issues with the Assay of Factor VIII Activity in Plasma and Factor VIII Concentrates , 2000, Thrombosis and Haemostasis.

[100]  Wilde.  Protease inhibitor therapy and bleeding , 2000, Haemophilia : the official journal of the World Federation of Hemophilia.

[101]  L. Cowan,et al.  Mortality among males with hemophilia: relations with source of medical care. The Hemophilia Surveillance System Project Investigators. , 2000, Blood.

[102]  J. Gill,et al.  Home Treatment of Mild to Moderate Bleeding Episodes Using Recombinant Factor VIIa (Novoseven) in Haemophiliacs with Inhibitors , 1998, Thrombosis and Haemostasis.

[103]  C. Kessler,et al.  Advances in carrier detection in haemophilia , 1998, Haemophilia : the official journal of the World Federation of Hemophilia.

[104]  Adam I. Wacey,et al.  The factor VIII Structure and Mutation Resource Site: HAMSTeRS version 4 , 1998, Nucleic Acids Res..

[105]  B. Nielsen,et al.  Recombinant Factor IX , 1997, Thrombosis and Haemostasis.

[106]  J. T. ten Cate,et al.  Recombinant, B-domain Deleted Factor VIII (r-VIII SQ): Pharmacokinetics and Initial Safety Aspects in Hemophilia A Patients , 1997, Thrombosis and Haemostasis.

[107]  I. Warrier,et al.  F, Spiro I: Posttransplantation lymphoproliferative disorders in solid Nephrotic Syndrome as a Complication of Immune Tolerance in Hemophilia B , 1997 .

[108]  M. Goossens,et al.  Haemophilia B: database of point mutations and short additions and deletions, 7th edition , 1990, Nucleic Acids Res..

[109]  J. Katz,et al.  Factor IX inhibitors and anaphylaxis in hemophilia B. , 1997, Journal of pediatric hematology/oncology.

[110]  E. Rodríguez‐Merchán.  Pathogenesis, early diagnosis, and prophylaxis for chronic hemophilic synovitis. , 1997, Clinical orthopaedics and related research.

[111]  F. Rosendaal,et al.  Mortality in Patients with Hemophilia: Changes in a Dutch Population from 1986 to 1992 and 1973 to 1986 , 1995, Annals of Internal Medicine.

[112]  F E Preston,et al.  Factor VIII gene inversions in severe hemophilia A: results of an international consortium study. , 1995, Blood.

[113]  M. van den Berg,et al.  The Nijmegen Modification of the Bethesda Assay for Factor VIII:C Inhibitors: Improved Specificity and Reliability , 1995, Thrombosis and Haemostasis.

[114]  E. C. Rodríguez Merchán.  The haemophilic pseudotumour , 1995, International Orthopaedics.

[115]  H. Pettersson,et al.  A longitudinal study of orthopaedic outcomes for severe factor‐VIII‐deficient haemophiliacs , 1994, Journal of internal medicine.

[116]  M. Manco‐Johnson,et al.  Results of secondary prophylaxis in children with severe hemophilia , 1994, American journal of hematology.

[117]  J. Luck,et al.  Hemarthrosis and synovitis associated with hemophilia: clinical use of P-32 chromic phosphate synoviorthesis for treatment. , 1994, Radiology.

[118]  U. Martinowitz,et al.  Dental extractions in patients with bleeding disorders. The use of fibrin glue. , 1993, Oral surgery, oral medicine, and oral pathology.

[119]  S. Schulman,et al.  Adjusted dose continuous infusion of factor VIII in patients with haemophilia A , 1992, British journal of haematology.

[120]  J. Fernández,et al.  Update of 156 episodes of central nervous system bleeding in hemophiliacs. , 1992, Haemostasis.

[121]  C. Kasper,et al.  Response of patients with mild and moderate hemophilia A and von Willebrand's disease to treatment with desmopressin. , 1985, Annals of internal medicine.

[122]  C. Kitchens,et al.  Spontaneous intra-abdominal hemorrhage in hemophilia. , 1984, Archives of internal medicine.

[123]  C. Kitchens.  Occult hemophilia. , 1980, The Johns Hopkins medical journal.

[124]  Björn Gustavii,et al.  FETOSCOPY , 1979, Acta obstetricia et gynecologica Scandinavica.

[125]  C. Mcmillan,et al.  SEVERE FACTOR VIII AND FACTOR IX DEFICIENCY IN FEMALES: 629 , 1978 .

[126]  C. Kitchens.  Retropharyngeal hematoma in a hemophiliac. , 1977, Southern medical journal.

[127]  D. Green,et al.  Proceedings: A more uniform measurement of factor VIII inhibitors. , 1975, Thrombosis et diathesis haemorrhagica.

[128]  J. Lewis,et al.  Heckathorn's disease: variable functional dificiency of antihemophilic factor (factor VIII). , 1975, Blood.

[129]  R. Biggs,et al.  The Mode of Action of Antibodies which Destroy Factor VIII , 1972, British journal of haematology.